iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. SPY
5. ACN
6. IBM
7. PFE
8. TSLA
9. DPZ
10. NVDA

Go back to iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
IBIO, Inc. (NASDAQ: IBIO) Delayed: 1.70 -0.04 (2.3%)
Previous Close $1.74    52 Week High $0.80 
Open $1.70    52 Week Low $0.34 
Day High $1.75    P/E N/A 
Day Low $1.68    EPS $-0.08 
Volume 153,748       

IBIO, Inc. (NASDAQ: IBIO) Delayed: 1.70 -0.04 (2.3%)
Previous Close $1.74    52 Week High $0.80 
Open $1.70    52 Week Low $0.34 
Day High $1.75    P/E N/A 
Day Low $1.68    EPS $-0.08 
Volume 153,748